# Shaquille O'Neal Credits Zepbound for Sleep Apnea Improvement and Weight Loss
Shaquille O'Neal recently shared that Zepbound, a GLP-1 receptor agonist medication, helped him lose weight and improve his sleep apnea symptoms. The former NBA star's endorsement highlights an emerging pattern in how these weight-loss drugs may benefit conditions linked to obesity.
Sleep apnea develops when excess weight narrows the airway, causing breathing interruptions during sleep. When patients lose weight, airway obstruction decreases, often reducing apnea severity. Research supports this connection. Studies show that even modest weight loss of 5 to 10 percent can meaningfully improve sleep apnea symptoms in people with obesity.
Zepbound contains semaglutide, the same active ingredient in Ozempic and Wegovy. The medication works by slowing gastric emptying and increasing feelings of fullness, leading patients to eat less and lose weight. FDA approval came in November 2023 specifically for weight management in people with obesity or overweight conditions with weight-related complications.
O'Neal's experience reflects what researchers are observing in clinical settings. Weight loss from GLP-1 medications can trigger improvements across multiple obesity-related conditions simultaneously, including type 2 diabetes, cardiovascular strain, and sleep disorders. This interconnected health benefit occurs because obesity itself drives or worsens these conditions.
However, doctors stress that GLP-1 medications work best alongside lifestyle changes. Improved diet, regular physical activity, and sleep hygiene remain foundational. The medications suppress appetite, but they don't replace the behavioral shifts needed for long-term success.
O'Neal's openness about using Zepbound contributes to broader conversations around pharmaceutical treatment for obesity. Public figures sharing their experiences reduce stigma and